BioCryst Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2011 Financial Results RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial r

First Page		Document Content
Acetamides Alcohols Guanidines Peramivir Clinical research Forodesine BioCryst Pharmaceuticals Clinical trial Allopurinol Chemistry Pharmacology Medicine		BioCryst Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2011 Financial Results RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial r Add to Reading List Source URL: files.shareholder.com Download Document from Source Website File Size: 24,67 KB Share Document on Facebook

	February 15, 2010 Shionogi & Co., Ltd. Shionogi Files an Additional Application for Pediatric Use of “RAPIACTA®’’ a Novel Anti-viral Drug for Influenza DocID: 19Yw2 - View Document
	January 13, 2010 Shionogi & Co., Ltd. Shionogi Receives Marketing and Manufacturing Approval of a Novel Anti-viral Drug for Influenza, “RAPIACTA 300mg Bag for Intravenous Drip Infusion” and DocID: 19A13 - View Document
	Shionogi & Co., Ltd. Shionogi Receives an Approval for an Additional Indication for Pediatric Use of RAPIACTA®, a Novel Anti-viral Drug for Influenza DocID: 19yiq - View Document
	January 26, 2010 Shionogi & Co., Ltd. A Novel Anti-viral Drug for Influenza, “RAPIACTA 300mg Bag for Intravenous Drip Infusion” and “RAPIACTA 150mg Vial for Intravenous Drip Infusion” Launch DocID: 19gAH - View Document
	Health Advisory: Influenza in Health Care Settings DocID: 14ZyG - View Document